CRANBURY, N.J., Nov. 5, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced updated data from an open-label, Phase 2 extension study (Study 205/FAB-CL-205) to investigate the long-term safety, tolerability and pharmacodynamics of migalastat HCl in 23 patients with Fabry disease who completed an initial Phase 2 study. Amicus in collaboration with GlaxoSmithKline (GSK) is developing the investigational pharmacological chaperone Migalastat HCl for the treatment of Fabry disease. Results1 from Study 205 were presented at the American Society of Nephrology (ASN) Kidney Week 2012.
